Check Cap (MBAI) Aktsia Kursus

Check Cap Ltd is primarily active in the healthcare industry, specifically in the field of medical diagnostics.

The main competitors of Check Cap Ltd in the market include companies such as Exact Sciences Corporation, Cerner Corporation, and Medtronic plc.

Check Cap Ltd is a pioneering medical technology company founded in 2004. The company focuses on the development of innovative capsule-based solutions for the medical imaging industry. Check Cap Ltd specializes in developing the C-Scan® system, a patient-friendly device designed to detect colorectal polyps and other gastrointestinal abnormalities. With cutting-edge imaging technology and a commitment to improving patient care, Check Cap Ltd has become a leading player in the medical imaging industry. Known for its dedication to innovation and its focus on improving diagnostic procedures, Check Cap Ltd continues to make significant advancements in the field of gastrointestinal imaging.

Check Cap Ltd has achieved several significant milestones in its journey. Some notable achievements include the successful completion of clinical trials for its C-Scan system, which is a revolutionary ingestible capsule for colorectal cancer screening. The company has also obtained CE Mark approval for the C-Scan system, allowing it to be marketed and sold in Europe. In addition, Check Cap Ltd has entered into partnerships and collaborations with renowned healthcare institutions and industry leaders, further enhancing its position in the market. These milestones highlight Check Cap Ltd's commitment to developing innovative solutions for early detection and prevention of colorectal cancer.

Check Cap Ltd is primarily present in Israel, the United States, and Europe.

Check Cap Ltd is committed to upholding strong values and a clear corporate philosophy. As a company specializing in medical diagnostics, Check Cap prioritizes integrity, innovation, and excellence in its operations. By developing cutting-edge technologies, Check Cap aims to revolutionize the field of screening and early detection of colorectal cancer. The company's core philosophy revolves around patient care, providing non-invasive solutions for effective diagnosis. Check Cap Ltd strives to foster an environment of trust, transparency, and social responsibility, driving its commitment to improving healthcare outcomes and enhancing patients' lives.

7 analüütikut hindavad praegu Check Cap aktsiat: 6 soovitab osta, 1 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Check Cap teenib tulu 4,76 M USD ja kasumit aktsia kohta −0,16 USD.

Check Cap Analüütikute kurssizihtpunktid 2026

Praeguse kursiga kaubeldakse Check Cap aktsiaga 2,16 EUR (2,43 USD) juures.

Check Cap aktsia (MBAI) on noteeritud 3 börsil, sh: NASDAQ (CHEK), Frankfurt (7CC.F), München (7CC.MU).

Check Cap Ltd is a research-based medical technology company based in Israel. It develops products for the prevention, diagnosis, and monitoring of gastroenterological diseases, with its core product being the C-Scan®. The C-Scan® is a non-invasive, capsule-based technology that allows for the scanning of the entire digestive tract to detect potential tumors or other abnormalities early on. It offers an alternative to traditional colonoscopies and improves diagnostic accuracy. The C-Scan® is easy to use, painless, and requires no prior preparation or cleaning of the colon. Check Cap also conducts clinical studies to develop and test medications for gastroenterological diseases and works on new technologies for better visualization of the digestive tract. Its business model combines research and development, clinical studies, product development, and partnerships with other companies and institutions. With its innovative technology, Check Cap has the potential to change the way gastroenterological diseases are diagnosed, treated, and monitored.

oodatav Check Cap käive on 4,76 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.

oodatav Check Cap kasum on −145 800,00 USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.

Võrdlusarvud hinna ja kasumiga (P/E) Check Cap jaoks on praegu −14,84. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Check Cap aktsia väärtust.

Kursuse ja müügimahu suhe (P/S) Check Cap jaoks on praegu 0,45. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Check Cap aktsia jaoks.

Eulpooli kvaliteedinäitaja Check Cap jaoks on 3/10.

Check Cap ISIN on IL0011336851. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.

Check Cap WKN on A14QUF. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.

Check Cap ticker on MBAI. Ticker-sümbol kasutatakse Check Cap aktsiate kauplemiseks börsil.